Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9532921 | 1.00 | OPRK1 (0.34) | OPRK1NPC1RAB9AKMT2AGAA | |
| SCHEMBL9532910 | 1.00 | OPRK1 (0.34) | OPRK1NPC1RAB9AKMT2AGAA | |
| SCHEMBL8359388 | 1.00 | OPRK1 (0.34) | OPRK1NPC1RAB9AKMT2AGAA | |
| SCHEMBL2827553 | 1.00 | OPRK1 (0.34) | OPRK1NPC1RAB9AKMT2AGAA | |
| Hydrochloric Acid SCHEMBL3114222 | 0.98 | OPRK1 (0.33) | OPRK1NPC1RAB9AKMT2AGAA | |
| SCHEMBL29187947 | 0.86 | GAA (0.33) | OPRK1NPC1RAB9AKMT2AGAA | |
| SCHEMBL29936637 | 0.86 | GAA (0.33) | OPRK1NPC1RAB9AKMT2AGAA | |
| SCHEMBL20598843 | 0.86 | GAA (0.33) | OPRK1NPC1RAB9AKMT2AGAA | |
| SCHEMBL30863789 | 0.84 | CHRNB2 (0.40) | OPRK1GAA | |
| SCHEMBL18956885 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919909-B1 | SYNTHETIC METHODS AND INTERMEDIATES FOR STEREOISOMERIC COMPOUNDS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | ARMETHEON INC (US) | 2013-08-21 | — | — | EP | claimed |
| EP-4568951-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-117843552-A | Resolution method of cis-4-amino-3-methoxypiperidine-1-formate optical isomer | 中国医学科学院药物研究所 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024035627-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-3356361-A1 | HYDROXYALKYL THIADIAZOLE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-08 | — | — | EP | disclosed |
| EP-3255993-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3233827-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016130444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016096686-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| EP-2925322-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-10-07 | — | — | EP | disclosed |
| US-5863923-A | TREATMENT OF ANXIETY, PSYCHOSIS, SCHIZOPHRENIA, DRUG ABUSE, IRRITABLE BOWEL SYNDROME | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-26 | — | — | US | disclosed |
| WO-1999002496-A1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
| US-5674868-A | ADMINISTERING TO TREAT DISORDERS SUCH AS ANXIETY, PSYCHOSIS, DEPRESSION, SCHIZOPHRENIA, DURG ABUSE, MIGRAINE, EMESIS AND IRRITABLE BOWEL SYNDROME | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-10-07 | — | — | US | disclosed |
| EP-0669919-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012494-A1 | USE OF DIMETHYLBENZOFURANS AND DIMETHYLBENZOPYRANS AS 5-HT3 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-06-09 | — | — | WO | disclosed |
| EP-0251417-B1 | 4-(AROYLAMINO) PIPERIDINEBUTANAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-14 | — | — | EP | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |